The efficacy of PI3K/Akt/mTOR pathway inhibitors in combination with TRAIL has been previously demonstrated (28,39,40), while the effect of BKM120 and TRAIL co-treatment has not been examined in glioma. The gene discussed is MTOR; the disease is central nervous system cancer.